[CLSN] Celsion Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.36 Change: 0.01 (2.77%)
Ext. hours: Change: 0 (0%)

chart CLSN

Refresh chart

Strongest Trends Summary For CLSN

CLSN is in the medium-term down -24% below S&P in 1 year. In the long-term down -99% below S&P in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company?s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-45.29% ROE-101.39% ROI-58.71%
Current Ratio2.98 Quick Ratio Long Term Debt/Equity0.25 Debt Ratio0.39
Gross Margin Operating Margin-5185.2% Net Profit Margin-5415.2% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-880 K Cash From Investing Activities1.74 M Cash From Operating Activities-5.94 M Gross Profit
Net Profit-7.01 M Operating Profit-6.59 M Total Assets59.78 M Total Current Assets30.67 M
Total Current Liabilities10.29 M Total Debt8.94 M Total Liabilities33.08 M Total Revenue120 K
Technical Data
High 52 week2.79 Low 52 week1.36 Last close1.71 Last change3.01%
RSI54.05 Average true range0.13 Beta0.48 Volume760.88 K
Simple moving average 20 days2.4% Simple moving average 50 days-1.22% Simple moving average 200 days-12.81%
Performance Data
Performance Week-6.04% Performance Month-2.29% Performance Quart-1.72% Performance Half-22.97%
Performance Year-35.47% Performance Year-to-date21.28% Volatility daily3.52% Volatility weekly7.87%
Volatility monthly16.12% Volatility yearly55.84% Relative Volume626.49% Average Volume97.87 K
New High New Low


2020-05-15 08:00:10 | Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-08 09:00:10 | Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020

2020-04-23 08:30:10 | Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program

2020-04-17 10:04:24 | If You Had Bought Celsion NASDAQ:CLSN Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today

2020-04-15 08:30:10 | Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

2020-03-26 21:39:48 | Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT

2020-03-26 09:00:00 | Celsion Corp. to Host Earnings Call

2020-03-26 08:00:10 | Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

2020-03-25 16:15:10 | Celsion Corporation Reports 2019 Financial Results and Provides Business Update

2020-03-23 08:00:10 | Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

2020-03-19 08:30:10 | Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020

2020-03-19 08:00:10 | Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

2020-03-03 08:30:10 | Celsion CEO Issues Letter to Stockholders

2020-02-28 08:45:10 | Celsion Corporation Prices $4.8 Million Registered Direct Offering

2020-02-25 06:20:37 | When Can We Expect A Profit From Celsion Corporation NASDAQ:CLSN?

2020-02-06 09:25:10 | Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer

2020-02-04 08:30:10 | Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference

2020-01-20 05:41:25 | Does Celsion Corporation NASDAQ:CLSN Have A High Beta?

2020-01-15 16:34:09 | Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

2020-01-15 08:22:01 | Momenta MNTA Provides Pipeline Updates, Stock Rallies

2020-01-14 08:53:01 | Ultragenyx Provides Preliminary Crysvita 2019 Revenues

2020-01-09 16:47:09 | Applied Therapeutics Up on Positive Galactosemia Study Data

2020-01-07 09:59:02 | Protagonist PTGX Starts Study on PTG-300 for Blood Disorder

2020-01-07 09:19:02 | aTyr LIFE Surges on Collaboration Deal With Kyorin Pharma

2019-12-23 14:15:51 | Hedge Funds Have Never Been This Bullish On Celsion Corporation CLSN

2019-12-18 08:00:10 | Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

2019-12-17 08:00:10 | Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer NOL Program

2019-12-15 08:10:30 | Should You Be Pleased About The CEO Pay At Celsion Corporation's NASDAQ:CLSN

2019-11-15 20:52:15 | Edited Transcript of CLSN earnings conference call or presentation 15-Nov-19 4:00pm GMT

2019-11-14 16:05:00 | Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-14 08:00:00 | Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

2019-11-09 08:40:55 | If You Had Bought Celsion NASDAQ:CLSN Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today

2019-11-08 08:30:00 | Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

2019-11-05 08:00:00 | Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

2019-11-04 08:00:00 | Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

2019-10-04 07:52:22 | Is Celsion NASDAQ:CLSN Using Debt In A Risky Way?

2019-10-01 08:00:00 | Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

2019-09-30 14:30:00 | Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

2019-09-23 08:00:00 | Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association ILCA Annual Conference

2019-09-04 06:32:17 | Market Sentiment Around Loss-Making Celsion Corporation NASDAQ:CLSN

2019-08-27 08:00:00 | Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

2019-08-19 14:53:39 | Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT

2019-08-14 16:30:00 | Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update

2019-08-13 08:01:00 | Celsion Announces Publication of Results of National Institutes of Health NIH Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology

2019-08-09 08:30:00 | Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities

2019-08-08 08:30:00 | Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019

2019-08-06 10:30:02 | Will Celsion CLSN Report Negative Q2 Earnings? What You Should Know

2019-08-05 09:00:00 | Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer

2019-08-05 07:31:10 | Before You Buy Celsion Corporation NASDAQ:CLSN, Consider Its Volatility

2019-06-20 08:30:00 | Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands